Newron Pharmaceuticals S.p.A. (SIX: NWRN)

https://www.newron.com

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on novel therapies for diseases of the central nervous system and pain. Phase 3 trials of safinamide are currently ongoing for the treatment of Parkinson's disease (PD). As per the agreement signed with Newron in 2006, Merck Serono, a division of Merck KGaA, Darmstadt, Germany ("Merck Serono"), has exclusive worldwide rights to develop, manufacture and commercialize the compound in PD, Alzheimer's disease, and other therapeutic applications. Newron Pharmaceuticals S.p.A. is domiciled in Bresso, Italy. Newron Pharmaceuticals S.p.A.'s Italian company registration code is 02479490126 (Milan) and its financial period is the calendar year. Newron Pharmaceuticals S.p.A. is the parent company of (i) Newron Suisse SA, a clinical development fully owned subsidiary based in Basel (Switzerland) established during 2007; and (ii) Hunter-Fleming Limited, a private biopharmaceutical company based in Bristol (United Kingdom) and focused on neurodegenerative and inflammatory disorders, which has been acquired in 2008. As at 26 September 2011, to the best of the company's knowledge, the largest shareholders of Newron Pharmaceuticals S.p.A. by means of basic equity holdings are: Goodman and Company (ownership percentage 9.7%), Great Point Partners (9.1%), 3i Group plc (7.4%), NWB Investissements S.p.r.l. (5.7%), TVM Life Science Ventures VI GmbH & Co. KG (3.8%) and Aviva Investors (3.2%). In connection with the Transaction, the distribution of the Consideration Shares and Consideration Options to be issued to Newron's shareholders is based on their relative holdings in Newron Pharmaceuticals S.p.A. Newron's shares are listed on the SIX Swiss Exchange. For more information, visit www.newron.com *

	Start	2004-12-01 existent
	Industry	Xadago®
	Industry 2	pain drug
	Person	Weber, Stefan (Newron Pharmaceuticals 201504 CEO before CFO)

	Street	21 Via Ludovico Ariosto
	City	20091 Bresso (MI)
	Tel	+39-02-6103451
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2016-12-31)
	Currency	EUR
	Annual sales	6,726,000 (revenue, total, consolidated (2016) 2016-12-31)
	Profit	-15,237,000 (2016-12-31)
	Cash	42,948,000 (2016-12-31)

		* Document for »About Section«:

		Record changed: 2026-05-02